These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 38936303

  • 1. Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4.
    Yang M, Yan R, Sha R, Wang X, Zhou S, Li B, Zheng Q, Cao Y.
    Clin Nutr; 2024 Aug; 43(8):1769-1780. PubMed ID: 38936303
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation.
    Mao D, Guo J, Yang K, Yang F, Peng J, Jia X, Luo Z, Liu L, Yang E, Tang R, Lan H, Zheng Q.
    Biochem Biophys Res Commun; 2024 Nov 19; 734():150424. PubMed ID: 39083974
    [Abstract] [Full Text] [Related]

  • 3. Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet.
    Huang J, Li W, Liao W, Hao Q, Tang D, Wang D, Wang Y, Ge G.
    Food Funct; 2020 Nov 18; 11(11):9924-9935. PubMed ID: 33095225
    [Abstract] [Full Text] [Related]

  • 4. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.
    Gan L, Meng ZJ, Xiong RB, Guo JQ, Lu XC, Zheng ZW, Deng YP, Luo BD, Zou F, Li H.
    Acta Pharmacol Sin; 2015 May 18; 36(5):597-605. PubMed ID: 25891086
    [Abstract] [Full Text] [Related]

  • 5. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization.
    Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C.
    Nutrients; 2021 Feb 11; 13(2):. PubMed ID: 33670347
    [Abstract] [Full Text] [Related]

  • 6. Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway.
    Wu D, Liu Z, Wang Y, Zhang Q, Li J, Zhong P, Xie Z, Ji A, Li Y.
    Oxid Med Cell Longev; 2021 Feb 11; 2021():5599997. PubMed ID: 33953830
    [Abstract] [Full Text] [Related]

  • 7. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y, Sun X, Chen Y, Deng Y, Qian K.
    Eur J Pharmacol; 2015 Aug 15; 761():405-12. PubMed ID: 25967348
    [Abstract] [Full Text] [Related]

  • 8. Theaphenon E prevents fatty liver disease and increases CD4+ T cell survival in mice fed a high-fat diet.
    Coia H, Ma N, Hou Y, Permaul E, Berry DL, Cruz MI, Pannkuk E, Girgis M, Zhu Z, Lee Y, Rodriquez O, Cheema A, Chung FL.
    Clin Nutr; 2021 Jan 15; 40(1):110-119. PubMed ID: 32439267
    [Abstract] [Full Text] [Related]

  • 9. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
    Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, Tipoe GL.
    Eur J Nutr; 2014 Feb 15; 53(1):187-99. PubMed ID: 23515587
    [Abstract] [Full Text] [Related]

  • 10. Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.
    Chen C, Liu Q, Liu L, Hu YY, Feng Q.
    Mol Nutr Food Res; 2018 Jan 15; 62(1):. PubMed ID: 28799714
    [Abstract] [Full Text] [Related]

  • 11. Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice.
    Santamarina AB, Carvalho-Silva M, Gomes LM, Okuda MH, Santana AA, Streck EL, Seelaender M, do Nascimento CM, Ribeiro EB, Lira FS, Oyama LM.
    J Nutr Biochem; 2015 Nov 15; 26(11):1348-56. PubMed ID: 26300331
    [Abstract] [Full Text] [Related]

  • 12. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
    Baumeier C, Schlüter L, Saussenthaler S, Laeger T, Rödiger M, Alaze SA, Fritsche L, Häring HU, Stefan N, Fritsche A, Schwenk RW, Schürmann A.
    Mol Metab; 2017 Oct 15; 6(10):1254-1263. PubMed ID: 29031724
    [Abstract] [Full Text] [Related]

  • 13. Epigallocatechin gallate alleviates high-fat diet-induced hepatic lipotoxicity by targeting mitochondrial ROS-mediated ferroptosis.
    Ding SB, Chu XL, Jin YX, Jiang JJ, Zhao X, Yu M.
    Front Pharmacol; 2023 Oct 15; 14():1148814. PubMed ID: 37025486
    [Abstract] [Full Text] [Related]

  • 14. Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota.
    Dey P, Olmstead BD, Sasaki GY, Vodovotz Y, Yu Z, Bruno RS.
    J Nutr Biochem; 2020 Oct 15; 84():108455. PubMed ID: 32688217
    [Abstract] [Full Text] [Related]

  • 15. (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease.
    Ying L, Yan F, Zhao Y, Gao H, Williams BR, Hu Y, Li X, Tian R, Xu P, Wang Y.
    Clin Exp Pharmacol Physiol; 2017 Dec 15; 44(12):1180-1191. PubMed ID: 28815679
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.